One of the biggest challenges in treating pancreatic cancer is that even when a drug works, it may not work forever. Cancer cells can adapt and find ways to survive treatments that once kept them in check. For patients who already have limited treatment options, understanding how and why a drug might fail could make a critical difference.
Researchers at the MCW Cancer Center are learning to predict cancer’s next move, potentially finding ways to outsmart it before it escapes treatment. In a new study, the team discovered that different mutations in the KRAS gene, commonly mutated in the disease, determine how cancer cells develop resistance to the same drug. Their findings, recently published in Cancer Research, could help care teams anticipate resistance and prepare another treatment strategy before patients run out of time or options.
“The escape route is written into the mutation from the start, which means you can predict it instead of waiting to be surprised by it,” said Tommy McFall, PhD, Assistant Professor of Biochemistry and a lead co-author of the study
The discovery builds on years of work from the McFall Lab investigating how different KRAS mutations influence treatment response. Through collaboration with MCW’s multidisciplinary Pancreatic Cancer Team, that research is now helping guide treatment decisions for patients.
Different Mutations, Different Escape Routes
Building on that earlier research, the McFall Lab set out to understand how different KRAS mutations allow cancer to escape drugs designed to stop it.
Using genetically engineered pancreatic cancer cells, the team studied resistance to daraxonrasib, an investigational drug targeting KRAS. They discovered that cancer cells survived treatment in two very different ways, depending on their KRAS mutation:
- G12D: Cancer cells disarmed the drug by reducing a protein it needs to work, allowing the cells to survive treatment.
- G12R: Cancer cells found another way to grow by bypassing the drug entirely. But in doing so, the cells became more vulnerable to an existing cancer drug called trametinib.
“Escaping a drug isn’t free. To get around it, the tumor has to commit to a new way of signaling, and it becomes dependent on that new route,” Dr. McFall explained.
Importantly, neither escape route required a new genetic mutation. Instead, cancer cells changed how they used existing proteins, meaning standard genetic testing alone could miss what was happening.
The team then had an opportunity to investigate these findings in a patient with advanced pancreatic cancer carrying the G12R mutation. After five lines of treatment, he had few options remaining, and there was little published evidence to guide the next move. When researchers analyzed his tumor, they found the same resistance mechanism they had identified in the laboratory.
Using magnetic 3D bioprinting, they assembled the patient’s cancer cells into tiny rings to rapidly test potential drugs. Within 48 hours, the tests showed that his cancer cells were sensitive to trametinib. Those results helped guide a sixth-line combination treatment.
“We had to figure out his specific escape route in real time, while he was still well enough to be treated. That window was narrow,” Dr. McFall said. “We got there, and the treatment we chose gave him about five months of disease control after two experimental drugs that had failed within weeks.”
Racing Against Resistance
For patients with advanced pancreatic cancer, finding another effective treatment can become a race against time. This study brought together specialists in medical and surgical oncology, radiology, biochemistry, tissue engineering, and MCW’s Molecular Tumor Board, each contributing expertise to understand the patient’s resistance and identify another treatment option.
Working closely with lead co-author Mandana Kamgar, MD, MPH, and MCW’s Pancreatic Cancer Team, Dr. McFall helped connect laboratory discoveries with clinical decision-making, using findings from the patient’s own tumor to guide his care.
The team is now working to test these findings in more patients, identify ways to overcome resistance in G12D cancers, and explore whether these escape routes could be blocked before they develop. While further research is needed, the findings point toward a future where care teams can anticipate how a patient’s cancer might adapt and have another treatment strategy ready before the first one fails.
“Usually you study resistance for years and publish long after the patient is gone,” Dr. McFall said. “Here, the entire study, from first patient contact to a treatment decision backed by his own tumor, came together within weeks.”
Read the full study in Cancer Research.
This work was supported by the MCW Mary Ann and Charles LaBahn Pancreatic Cancer Program and philanthropic gifts, including the Scott and Cynthia McAfee Fund for Pancreatic Cancer Precision Medicine, Craig Adelman Fund, Burkhardt Family Fund, and Byrne Scholar Fund.